Pathological Complete Response Linked to Neoadjuvant Anti-HER2 Survival

Pathological complete response predicts improved outcomes for early breast cancer patients given neoadjuvant HER2-targeted therapy...

ESMO members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.